Company News
Shilpa Medicare SEC Approval for OERIS Injectable
Shilpa Medicare received final SEC approval for marketing authorization of OERIS™, a novel extended-release ondansetron injection.
OERIS™ is the world's first injectable providing 5-day antiemetic act
